semaglutide and als Full article: Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists AstraZeneca's Alexion halts ALS trial
Description
Continuing this discussion, we broaden the lens to the developing litigation environment and additional regulatory scrutiny that can affect manufacturers, pharmacies, telehealth providers, and other stakeholders across the GLP1 ecosystem
Learn what 2025 research reveals.
The FDA has approved the first oral GLP-1 for weight loss
Ozempics half-life is ~7 days
Its a prescription drug with many uses, including treating type 2 diabetes in certain adults.
GLP-1 medications are becoming one of the most important workplace health and benefits topics
